Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin in Bronchiolitis Obliterans Syndrome after Lung Transplantation
2005-003893-46Phase 4Completed
- Sponsor
- KU Leuven
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of azithromycin in Bronchiolitis Obliterans Syndrome (BOS), chronic lung allograft dysfunction (CLAD) and Lung allograft rejection (LAR), sponsored by KU Leuven. Primary endpoints: Prevalence of chronic rejection at 1 year post-transplant, Prevalence of chronic rejection at 2 years post-transplant and 2 more. Started Oct 2009; status: completed.
02
Drugs
azithromycin
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)chronic lung allograft dysfunction (CLAD)Lung allograft rejection (LAR)
Beyond the preview
Go deeper on 2005-003893-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003893-46.